if you want to know more there is a conference call this Thursday with the CEO explaining the road ahead. Then compare pre clinical results to AGN and NYR are far superior when it comes to stroke and traumatic brain injury based off mono therapy. AGN was a 70 million market cap pre clinical studies which is where NYR are and currently sit at a 18 million market cap with 10 million in cash. NYR has a lot to rerate in the period ahead and the Walter reed study with the US army that starts this month will accelerate the rise.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.025(10.6%) |
Mkt cap ! $54.83M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 26.5¢ | 23.5¢ | $352.7K | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3600 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 4499 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |